BullFrog AI Enters Agreement with Global Pharma Company
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BFRG?
BullFrog AI announced a commercial agreement with a global pharmaceutical company to apply the company's proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder, accelerating the customer's drug discovery and clinical development program for this indication. The agreement also provides exclusive access to a target candidate
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFRG
About BFRG
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Artelo Biosciences and Others See Significant Stock Price Gains
- Artelo Stock Surge: Artelo Biosciences shares jumped over 23% in pre-market trading on Tuesday after announcing the closure of an $11 million private placement of common stock, indicating a strategic move to repay bridge debt and meet working capital needs, which could enhance the company's financial stability.
- Bullfrog AI's Strong Performance: Bullfrog AI shares soared more than 12% in Tuesday's pre-market session, building on a 107% gain from Monday, following an agreement with a major global pharmaceutical company to accelerate drug discovery and clinical development, showcasing the company's strategic partnerships in the biopharmaceutical sector.
- Hitek Global Stock Doubles: Hitek Global shares surged 110% in pre-market trading on Tuesday after closing a $3 million registered direct offering of Class A ordinary shares on Monday, despite a 98% decline year-to-date, indicating potential funding support for future business recovery.
- Market Sentiment Improves: U.S. equities were in the green during Tuesday's pre-market trading after President Trump expressed willingness to end the Iran war without fully reopening the Strait of Hormuz, with the SPDR S&P 500 ETF rising 0.92%, reflecting a renewed optimism among investors regarding market prospects.
See More
BFRG Stock Soars Over 100% Today — What’s Behind the Rise?
Stock Surge: Bullfrog AI Holdings Inc. (BFRG) shares rose over 114% in pre-market trading following the announcement of a deal with a major global pharmaceutical company.
Strategic Agreement: The agreement requires Bullfrog AI to utilize its bfLEAP program to identify and prioritize novel drug targets for major depressive disorder (MDD).
Development Goals: The company aims to accelerate its drug discovery and clinical development programs through this partnership.
Market Sentiment: Retail sentiment around Bullfrog AI is currently described as "extremely bullish," with high message volumes noted at the time of reporting.
See More
BullFrog AI Signs Agreement with Top Global Pharma Company
- Commercial Agreement Signed: BullFrog AI has entered into a commercial agreement with a top five global pharmaceutical company to utilize its bfLEAP® platform, significantly enhancing the Customer's drug discovery and development efficiency for major depressive disorder (MDD).
- Significant Market Potential: The MDD market was valued at over $8 billion in 2025 and is projected to grow at nearly 5% annually to exceed $11 billion by 2032, highlighting the strategic value of BullFrog AI in this sector.
- Technological Edge: BullFrog AI's bfLEAP® platform leverages causal network inference to provide drug developers with a clearer path for identifying drug targets, aiming to resolve multimodal biological complexities and reduce clinical trial failure rates.
- Future Collaboration Outlook: CEO Vin Singh emphasized that this agreement not only validates the company's technological capabilities but also indicates potential for further collaboration within the Customer's research and development portfolio.
See More
BULLFROG AI ENTERS INTO COMMERCIAL PARTNERSHIP WITH LEADING GLOBAL PHARMACEUTICAL FIRM TO DETERMINE AND PRIORITIZE THERAPEUTIC TARGETS FOR MAJOR DEPRESSIVE DISORDER
Commercial Agreement Announcement: Bullfrog AI has announced a commercial agreement with a top global pharmaceutical company.
Focus on Therapeutic Target: The partnership aims to identify and prioritize therapeutic targets for major depressive disorder.
See More
BullFrog AI Launches New Scenario-Based Decision Engine for R&D
- Technology Launch: BullFrog AI is set to launch a new scenario-based decision engine on March 25, 2026, aimed at enhancing its existing bfPREP™ and bfLEAP® platforms, thereby improving the intelligence workflow in drug development.
- Enhanced Decision-Making: The new engine utilizes proprietary algorithms to test portfolio decisions against multiple explicit scenarios, helping to identify options that perform well across various strategic futures, thus optimizing R&D strategies.
- Addressing Market Needs: With over $200 billion spent annually by life sciences and pharmaceutical companies on R&D and a staggering 90% clinical trial failure rate, the introduction of this technology aims to improve return on investment and mitigate R&D risks.
- Industry-Leading Advantage: According to BullFrog AI Founder and CEO Vin Singh, this technology is unique globally, providing more flexible strategic decision support that accelerates the drug discovery and development process.
See More
BullFrog AI Releases White Paper on Data Harmonization in Life Sciences
- Importance of Data Harmonization: BullFrog AI's white paper emphasizes that data harmonization is a hidden prerequisite for reliable AI/ML analysis, aiming to transform complex biomedical data into actionable insights through bfPREPTM, thereby enhancing drug development success rates.
- Technological Advantage: The company leverages bfPREPTM to quickly identify and standardize fragmented biomedical data, ensuring dataset reliability, allowing research teams to focus more on interpreting results and study design rather than data processing.
- Challenges in AI Pipelines: The white paper highlights that modern AI pipelines often fail in life sciences due to peculiarities in data processing, and BullFrog AI proposes a practical harmonization framework built on three pillars to address these issues and improve data analysis effectiveness.
- Enhancing Clinical Trial Success Rates: By utilizing bfPREPTM, BullFrog AI aims to reduce clinical trial failure rates, enabling teams to utilize data more efficiently and accelerate drug discovery and development processes, further solidifying its market position in the biopharma sector.
See More
Artelo Biosciences and Others See Significant Stock Price Gains
- Artelo Stock Surge: Artelo Biosciences shares jumped over 23% in pre-market trading on Tuesday after announcing the closure of an $11 million private placement of common stock, indicating a strategic move to repay bridge debt and meet working capital needs, which could enhance the company's financial stability.
- Bullfrog AI's Strong Performance: Bullfrog AI shares soared more than 12% in Tuesday's pre-market session, building on a 107% gain from Monday, following an agreement with a major global pharmaceutical company to accelerate drug discovery and clinical development, showcasing the company's strategic partnerships in the biopharmaceutical sector.
- Hitek Global Stock Doubles: Hitek Global shares surged 110% in pre-market trading on Tuesday after closing a $3 million registered direct offering of Class A ordinary shares on Monday, despite a 98% decline year-to-date, indicating potential funding support for future business recovery.
- Market Sentiment Improves: U.S. equities were in the green during Tuesday's pre-market trading after President Trump expressed willingness to end the Iran war without fully reopening the Strait of Hormuz, with the SPDR S&P 500 ETF rising 0.92%, reflecting a renewed optimism among investors regarding market prospects.
See More
BFRG Stock Soars Over 100% Today — What’s Behind the Rise?
Stock Surge: Bullfrog AI Holdings Inc. (BFRG) shares rose over 114% in pre-market trading following the announcement of a deal with a major global pharmaceutical company.
Strategic Agreement: The agreement requires Bullfrog AI to utilize its bfLEAP program to identify and prioritize novel drug targets for major depressive disorder (MDD).
Development Goals: The company aims to accelerate its drug discovery and clinical development programs through this partnership.
Market Sentiment: Retail sentiment around Bullfrog AI is currently described as "extremely bullish," with high message volumes noted at the time of reporting.
See More
BullFrog AI Signs Agreement with Top Global Pharma Company
- Commercial Agreement Signed: BullFrog AI has entered into a commercial agreement with a top five global pharmaceutical company to utilize its bfLEAP® platform, significantly enhancing the Customer's drug discovery and development efficiency for major depressive disorder (MDD).
- Significant Market Potential: The MDD market was valued at over $8 billion in 2025 and is projected to grow at nearly 5% annually to exceed $11 billion by 2032, highlighting the strategic value of BullFrog AI in this sector.
- Technological Edge: BullFrog AI's bfLEAP® platform leverages causal network inference to provide drug developers with a clearer path for identifying drug targets, aiming to resolve multimodal biological complexities and reduce clinical trial failure rates.
- Future Collaboration Outlook: CEO Vin Singh emphasized that this agreement not only validates the company's technological capabilities but also indicates potential for further collaboration within the Customer's research and development portfolio.
See More
BULLFROG AI ENTERS INTO COMMERCIAL PARTNERSHIP WITH LEADING GLOBAL PHARMACEUTICAL FIRM TO DETERMINE AND PRIORITIZE THERAPEUTIC TARGETS FOR MAJOR DEPRESSIVE DISORDER
Commercial Agreement Announcement: Bullfrog AI has announced a commercial agreement with a top global pharmaceutical company.
Focus on Therapeutic Target: The partnership aims to identify and prioritize therapeutic targets for major depressive disorder.
See More
BullFrog AI Launches New Scenario-Based Decision Engine for R&D
- Technology Launch: BullFrog AI is set to launch a new scenario-based decision engine on March 25, 2026, aimed at enhancing its existing bfPREP™ and bfLEAP® platforms, thereby improving the intelligence workflow in drug development.
- Enhanced Decision-Making: The new engine utilizes proprietary algorithms to test portfolio decisions against multiple explicit scenarios, helping to identify options that perform well across various strategic futures, thus optimizing R&D strategies.
- Addressing Market Needs: With over $200 billion spent annually by life sciences and pharmaceutical companies on R&D and a staggering 90% clinical trial failure rate, the introduction of this technology aims to improve return on investment and mitigate R&D risks.
- Industry-Leading Advantage: According to BullFrog AI Founder and CEO Vin Singh, this technology is unique globally, providing more flexible strategic decision support that accelerates the drug discovery and development process.
See More
BullFrog AI Releases White Paper on Data Harmonization in Life Sciences
- Importance of Data Harmonization: BullFrog AI's white paper emphasizes that data harmonization is a hidden prerequisite for reliable AI/ML analysis, aiming to transform complex biomedical data into actionable insights through bfPREPTM, thereby enhancing drug development success rates.
- Technological Advantage: The company leverages bfPREPTM to quickly identify and standardize fragmented biomedical data, ensuring dataset reliability, allowing research teams to focus more on interpreting results and study design rather than data processing.
- Challenges in AI Pipelines: The white paper highlights that modern AI pipelines often fail in life sciences due to peculiarities in data processing, and BullFrog AI proposes a practical harmonization framework built on three pillars to address these issues and improve data analysis effectiveness.
- Enhancing Clinical Trial Success Rates: By utilizing bfPREPTM, BullFrog AI aims to reduce clinical trial failure rates, enabling teams to utilize data more efficiently and accelerate drug discovery and development processes, further solidifying its market position in the biopharma sector.
See More
